Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Medtronic
Merck

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR CYANOCOBALAMIN CO-57


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Cyanocobalamin Co-57

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004495 ↗ Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis Completed Georgetown University N/A 1999-06-01 OBJECTIVES: I. Compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia. II. Determine the requirement of co-supplementation with extra pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) daily in these patients. III. Assess the safety and tolerability of this therapy in these patients.
NCT00004734 ↗ Vitamin Therapy for Prevention of Stroke Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 3 1996-09-01 A stroke occurs when part of the brain is damaged from lack of normal blood supply. This may result in difficulty with feeling, speech, muscle strength or coordination, movement, thinking, or other brain functions. Having a stroke increases the risk of another stroke occurring in the future. Higher blood levels of a natural chemical known as homocysteine may contribute to hardening of the arteries in the brain or heart and increase the risk of stroke or heart attack. Folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cyanocobalamin) may lower blood levels of homocysteine and reduce the risk of having another stroke or a heart attack.
NCT00032435 ↗ Homocysteine Study (HOST) Completed Abbott Diagnostics Division Phase 3 2001-05-01 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 ↗ Homocysteine Study (HOST) Completed Pan American Laboratories Phase 3 2001-05-01 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cyanocobalamin Co-57

Condition Name

Condition Name for Cyanocobalamin Co-57
Intervention Trials
Vitamin B12 Deficiency 3
End Stage Renal Disease 2
Anaemia 2
Stroke 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cyanocobalamin Co-57
Intervention Trials
Vitamin B 12 Deficiency 5
Lymphoma 4
Lymphoma, T-Cell 3
Carcinoma, Transitional Cell 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cyanocobalamin Co-57

Trials by Country

Trials by Country for Cyanocobalamin Co-57
Location Trials
United States 195
India 9
Hungary 7
Argentina 5
France 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cyanocobalamin Co-57
Location Trials
New York 12
Texas 12
Illinois 11
California 11
Pennsylvania 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cyanocobalamin Co-57

Clinical Trial Phase

Clinical Trial Phase for Cyanocobalamin Co-57
Clinical Trial Phase Trials
Phase 4 3
Phase 3 5
Phase 2 18
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cyanocobalamin Co-57
Clinical Trial Phase Trials
Completed 29
Terminated 3
Not yet recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cyanocobalamin Co-57

Sponsor Name

Sponsor Name for Cyanocobalamin Co-57
Sponsor Trials
National Cancer Institute (NCI) 8
Spectrum Pharmaceuticals, Inc 7
Acrotech Biopharma LLC 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cyanocobalamin Co-57
Sponsor Trials
Other 32
Industry 19
NIH 9
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Moodys
Merck
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.